-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the incomplete statistics of the Medicine Cloud Studio, 3,682 quality standards have passed the consistency evaluation, and 421 quality standards have been reviewed by more than three companies (including three companies).
According to the statistics of the Medicine Cloud Studio, from January 15, 2022 to January 22, 2022, 19 new varieties (deemed) passed the consistency evaluation, of which 2 were the first in the country to pass the evaluation
.
details as follows:
Hengrui Medicine: Nimodipine Oral Solution
Hengrui Medicine: Nimodipine Oral Solution Nimodipine is a second-generation dipine drug and is a commonly used antihypertensive drug in clinical practice
.
Nimodipine is mainly used for the improvement of blood circulation in the recovery period of acute cerebrovascular disease, the protection of ischemic neurons and the treatment of vascular dementia
In addition, Nimodipine Oral Liquid is one of the first varieties to be encouraged to develop and declare the Children's Drug List
.
In December 2017, Hengrui submitted the drug's marketing application, which took 4 years to review and was finally approved for marketing
It is reported that two other domestic companies have also applied for the drug.
Guangdong Jincheng Jinsu submitted a listing application in January 2021, and Zhejiang Guojing Pharmaceutical just applied for listing in January this year
.
According to data from Minet.
com, the sales of nimodipine in China's public medical institutions exceeded 700 million yuan in mid-2020.
In the first half of 2021, there was a slight year-on-year decline.
Bayer had the largest market share
.
Beijing Hanmei Pharmaceutical Co.
, Ltd.
: Amlodipine Losartan Potassium Tablets (I)
, Ltd.
: Amlodipine Losartan Potassium Tablets (I)
Amlodipine and Losartan is a compound antihypertensive drug, suitable for the treatment of essential hypertension in patients whose blood pressure cannot be adequately controlled by monotherapy
.
In September 2019, Beijing Hanmi Pharmaceuticals took the lead in submitting a new category 3 generic drug application for amlodipine and losartan potassium tablets (I).
After two and a half years of review, it was finally approved for marketing recently.
The first review
.
At the same time, the company has also launched the layout of amlodipine and losartan potassium tablets (II), and has completed the second round of data supplementation, and it will be just around the corner to win the first copy
The latest national review data report:
The latest national review data report:According to the incomplete statistics of the Medicine Cloud Studio, 3,682 quality standards have passed the consistency evaluation, and 421 quality standards have been collected by more than three (including three) companies
3682 421
